The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to new research from Memorial Sloan-Kettering Cancer Center.
Fuente : http://www.eurekalert.org/pub_releases/2013-06/msc...
Fuente : http://www.eurekalert.org/pub_releases/2013-06/msc...